Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes

Launched by GARVAN INSTITUTE OF MEDICAL RESEARCH · Feb 6, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at how a medication called Tirzepatide affects metabolism in people with Type 1 Diabetes (T1D). Tirzepatide is a new type of treatment that helps manage blood sugar levels by working on hormones that control insulin and appetite. Participants in the study will have their insulin sensitivity and hormone levels measured before and after four weeks of using Tirzepatide. The results will be compared to a group of adults without diabetes to see how metabolism differs between those with and without T1D.

To be eligible for this trial, participants must be between 18 and 55 years old, have a body mass index (BMI) of 27 or higher, and have been diagnosed with Type 1 Diabetes for at least two years. They should also be using an automated insulin delivery system and have a controlled blood sugar level. However, certain health conditions and recent treatments might disqualify someone from participating. If eligible, participants can expect to take Tirzepatide for four weeks and undergo several tests to monitor their metabolic response. It’s important to know that the trial is not yet recruiting, so those interested will need to wait until it starts.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • age 18-55 years
• • BMI ≥ 27 kg/m2
• • HbA1c ≤ 9.0%
• • insulin delivery using an automated insulin delivery system
• • at least 2 years since diagnosis of type 1 diabetes
• Exclusion Criteria:
• • TZP or GLP-1 receptor agonist in last 3 months; metformin or sodium glucose co-transporter 2 (SGLT2) inhibitor in the last 6 weeks; steroids, antipsychotics, immunosuppressants in the last 6 weeks.
• • Hypoglycemic unawareness or severe hypoglycemia last 6 months.
• • History of seizure disorder.
• • History of weight loss surgery.
• • eGFR \<60 mL/min/1.73 m2.
• • Liver disease (known cirrhosis, LFTs \> 3x upper limit of normal).
• • Active malignancy.
• • Pregnant, breastfeeding, planning pregnancy within 6 months, or not using adequate contraception.
• • History of cardiovascular disease, or coronary event or stroke in last 3 months
• • Hemoglobin level \< 13.5 g/dL